Table 1 Baseline characteristics of 400 patients with locoregionally advanced nasopharyngeal carcinoma
| Â | Ever 193(48.3%) | Never 207(51.8%) | P value |
|---|---|---|---|
Age(yr), median(range) | 45(18-63) | 41(18-65) | 0.969 |
Gender | Â | Â | <0.001 |
Female | 3(1.6) | 84(40.6) | Â |
Male | 190(98.4) | 123(59.4) | Â |
T stage | Â | Â | Â |
1-2 | 29(15.0) | 28(13.5) | 0.668 |
3-4 | 164(85.0) | 179(86.5) | Â |
N stage | Â | Â | 0.541 |
0-1 | 92(47.7) | 105(50.7) | Â |
2-3 | 101(52.3) | 102(49.3) | Â |
Clinical stage | Â | Â | 0.222 |
3 | 103(53.4) | 123(59.4) | Â |
4 | 90(46.6) | 84(40.6) | Â |
Treatment arm | Â | Â | 0.617 |
IC + CCRT | 99(51.3) | 101(48.8) |  |
IC + RT | 94(48.7) | 106(51.2) |  |
RT dose(Gy),median(range) | 72(68-78) | 72(68-78) | 0.773 |
CT course, median(range) | 3(1-5) | 3(1-5) | 0.079 |
RT interruption | Â | Â | 0.936 |
yes | 4(2.1) | 3(1.4) | Â |
no | 189(97.9) | 204(98.6) | Â |
AMT | Â | Â | 0.559 |
1-2 | 182(93.8) | 196(95.1) | Â |
3-4 | 11(6.2) | 10(4.9) | Â |
VCA-IgA | Â | Â | 0.833 |
Positive(≥1:80) | 174(90.2) | 187(96.6) |  |
Negative(<1:80) | 19(9.8) | 19(3.4) | Â |
EA-IgA | Â | Â | 0.181 |
Positive(≥1:10) | 151(78.2) | 172(83.6) |  |
Negative(<1:10) | 42(21.8) | 34(16.4) | Â |
Median follow-up yr, median(range) | 6.5(0.2-9.0) | 6.9(0.6-9.3) | 0.236 |